Sumitomo Corporation entered into contract with Revorf

Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies

Sumitomo Corporation has invested in Revorf, a biotech venture that develops medical testing and supports drug discovery, and has concluded an exclusive worldwide agency agreement excluding Japan for Revorf's infertility and miscarriage testing business that it operates in Japan.

In Japan, it is believed that there are approximately 500,000 female infertility patients and approximately 300,000 to 500,000 women suffering from recurrent pregnancy loss, but roughly half of the cases are difficult to treat because the cause is unknown, making this a major social issue in Japan, where the birthrate is declining.In addition, it is said that approximately 17.5 percent of the adult population worldwide (approximately one in six people) suffers from infertility, and there is an urgent need to increase access to affordable, high-quality treatment.

Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies, which are thought to cause miscarriage and thrombosis, accounting for approximately 20% of miscarriage cases, and have been reported to be related to infertility in recent years.

Clinical studies have confirmed that when the test results were positive, the pregnancy rate was more than twice as high in infertility cases and the birth rate was approximately 1.7 times higher in miscarriage cases in groups that underwent the corresponding treatment.

Revolf will begin its testing business in 2022 and is deploying the test at more than 140 medical institutions nationwide. If the test is approved as advanced medical care in the future, it is expected that it will become even more popular as it is expected to be eligible for medical cost subsidies from local governments, reducing patients' out-of-pocket expenses.